Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Biogen will buy Fumapharm
June 5, 2006
| A version of this story appeared in
Volume 84, Issue 23
Biogen Idec has agreed to acquire Fumapharm AB, a Swiss developer of therapeutics derived from fumaric acid esters, for an undisclosed sum. The two firms also announced positive results from a Phase II study of BG-12, an oral fumarate they are jointly developing for the treatment of multiple sclerosis and psoriasis. As part of a restructuring last year, Biogen Idec announced plans to actively pursue relationships with other firms and academic institutions (C&EN, Sept. 19, 2005, page 9). Earlier this year, the company announced plans to acquire Conforma Therapeutics for $150 million.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter